港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫美概念股

615.910

-2.061-0.33%

漲家數：4

跌家數：9

平家數：- -

市盈率：- -

高：629.455

開：617.017

低：610.131

收：617.971

資料載入中...

三生製藥盤中異動快速拉昇5.06%

時代天使盤中異動快速拉昇5.20%報66.750港元

復鋭醫療科技盤中異動股價大漲5.08%報4.140港元

復星醫藥(02196.HK)複方匹可硫酸鈉顆粒上市申請獲批

阿斯达克财经

復星醫藥(02196.HK)鹽酸替那帕諾片上市申請獲批

阿斯达克财经

復星醫藥(02196.HK)鹽酸溴己新注射液藥品註冊申請獲受理

阿斯达克财经

復星醫藥(02196)：鹽酸溴己新注射液的藥品註冊申請獲受理

復星醫藥(02196)：鹽酸替那帕諾片的上市許可申請獲國家藥監局批准

復星醫藥：公司對Gland Pharma未來的長期表現充滿信心，並將繼續推動其在全球市場的發展和增長

復星醫藥：公司董事會已分別審議通過A股回購方案及H股回購方案

全球首款磷吸收抑制劑萬緹樂在中國獲批上市

南方财经网

真實生物二戰港交所：僅一款藥物上市分手復星後銷量暴跌在研管線青黃不接距上市遙遙無期

復星醫藥控股子公司鹽酸溴己新注射液獲受理研發投入164萬元

復星醫藥控股子公司複方匹可硫酸鈉顆粒獲批

復星醫藥控股子公司獲鹽酸替那帕諾片上市許可

復星醫藥(600196.SH)：複方匹可硫酸鈉顆粒上市註冊申請獲批准

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1593/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"醫美概念股","latestPrice":615.91016,"timestamp":1741334919528,"preClose":617.97076,"halted":0,"volume":98237105,"delay":0,"changeRate":-0.003334,"change":-2.060608,"pbRate":1.190795,"amount":537677282,"amplitude":0.031271,"prevYearClose":571.87146,"fiveDayClose":612.07,"twentyDayClose":570.981,"turnoverRate":0.004789,"marketCap":111057548872,"floatMarketCap":73073330248,"peRate":21.56404},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":629.45526,"amplitude":0.031271,"preClose":617.97076,"low":610.1307,"pbRate":"1.190795","latestPrice":615.91016,"volume":98237105,"delay":0,"open":617.01715,"prevYearClose":571.87146,"prevWeekClose":612.07,"prevMonthClose":612.07,"prevQuarterClose":571.871,"fiveDayClose":612.07,"twentyDayClose":570.981,"sixtyDayClose":575.728,"secType":"PLATE","market":"HK","turnoverRate":0.004789,"peRate":21.56404,"marketCap":111057548872,"floatMarketCap":73073330248,"timestamp":1741334919528,"nameCN":"醫美概念股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":4,"down":9,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:16,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514819482","title":"三生製藥盤中異動 快速拉昇5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514819482","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514819482?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 09:41","pubTimestamp":1740620499,"startTime":"0","endTime":"0","summary":"2025年02月27日早盘09时41分，三生制药股票出现异动，股价急速拉升5.06%。截至发稿，该股报7.480港元/股，成交量604.5万股，换手率0.25%，振幅5.20%。三生制药股票所在的药品行业中，整体跌幅为0.02%。其相关个股中，开拓药业-B、君圣泰医药-B、三生制药涨幅较大，振幅较大的相关个股有开拓药业-B、君圣泰医药-B、德琪医药-B，振幅分别为11.11%、7.83%、5.20%。三生制药公司简介：投资控股,及本集团主要在中国从事开发、生产、营销及销售生物医药产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227094139989433b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227094139989433b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01530","BK1161","BK1593","BK1583"],"gpt_icon":0},{"id":"2514816559","title":"時代天使盤中異動 快速拉昇5.20%報66.750港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514816559","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514816559?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 09:37","pubTimestamp":1740620276,"startTime":"0","endTime":"0","summary":"2025年02月27日早盘09时37分，时代天使股票出现波动，股价快速上涨5.20%。截至发稿，该股报66.750港元/股，成交量3.64万股，换手率0.02%，振幅4.33%。资金方面，该股资金流入190.56万港元，流出18.177万港元。时代天使股票所在的医疗及医学美容服务行业中，整体涨幅为0.13%。其相关个股中，时代天使、医渡科技、瑞尔集团涨幅较大，振幅较大的相关个股有艾迪康控股、时代天使、医脉通，振幅分别为5.03%、4.33%、4.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227093756abde83e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227093756abde83e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1593","BK1587","06699","BK1100"],"gpt_icon":0},{"id":"2514816388","title":"復鋭醫療科技盤中異動 股價大漲5.08%報4.140港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514816388","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514816388?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 09:35","pubTimestamp":1740620138,"startTime":"0","endTime":"0","summary":"2025年02月27日早盘09时35分，复锐医疗科技股票出现异动，股价急速上涨5.08%。截至发稿，该股报4.140港元/股，成交量14.56万股，换手率0.03%，振幅5.08%。资金方面，该股资金流入46.536万港元，流出7.8424万港元。复锐医疗科技股票所在的医疗设备及用品行业中，整体涨幅为0.16%。其相关个股中，百心安-B、复锐医疗科技、先健科技涨幅较大，振幅较大的相关个股有百心安-B、复锐医疗科技、威高股份，振幅分别为37.89%、4.57%、4.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270935389631d4e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270935389631d4e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01696","BK1100","BK1593","BK1585"],"gpt_icon":0},{"id":"2514813353","title":"復星醫藥(02196.HK)複方匹可硫酸鈉顆粒上市申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2514813353","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514813353?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 08:58","pubTimestamp":1740617880,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，控股子公司苏州二叶制药就复方匹可硫酸钠颗粒的上市注册申请，已于近日获国家药品监督管理局批准。该药品为复星医药自主研发的化学药品，主要用于结肠镜检查、X光检查前的肠道清洁准备，用于必要时在外科手术前清洁肠道。截至2025年1月，集团现阶段针对该药品累计研发投入约为853万元人民币。(gc/k)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-26 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131534109_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131534109_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420582/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0183","BK0175","BK1191","BK0096","BK1515","BK0196","BK0239","BK0060","BK0188","02196","BK0028","BK0012","600196","BK0187","BK1593"],"gpt_icon":0},{"id":"2514181803","title":"復星醫藥(02196.HK)鹽酸替那帕諾片上市申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2514181803","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514181803?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 08:54","pubTimestamp":1740617640,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，控股子公司上海复星医药产业获许可产品盐酸替那帕诺片(商品名“万缇乐”)，上市许可申请于近日获国家药品监督管理局批准，获批适应症为用于控制对磷结合剂疗效不充分或不耐受的慢性肾脏病(CKD)成人透析患者的血清磷水平。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-26 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180321105506149_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180321105506149_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420580/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0188","BK0175","BK0096","BK1515","BK1593","BK0196","BK0060","BK0012","02196","BK0028","BK0183","BK0187","BK1191","BK0239","600196"],"gpt_icon":0},{"id":"2514856645","title":"復星醫藥(02196.HK)鹽酸溴己新注射液藥品註冊申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856645","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514856645?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 22:42","pubTimestamp":1740580920,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，控股子公司重庆药友制药就盐酸溴己新注射液的药品注册申请于近日获国家药品监督管理局受理。盐酸溴己新注射液为集团自主研发的化学药品。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-26 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420477/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0183","BK0096","BK0196","BK0028","600196","BK0175","BK0188","BK1515","BK0012","BK0187","BK0239","BK1191","BK1593","BK0060","02196"],"gpt_icon":0},{"id":"2514880968","title":"復星醫藥(02196)：鹽酸溴己新注射液的藥品註冊申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2514880968","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514880968?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 18:33","pubTimestamp":1740566027,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，该公司控股子公司重庆药友制药有限责任公司就盐酸溴己新注射液(以下简称“该药品”)的药品注册申请于近日获国家药品监督管理局受理。盐酸溴己新注射液为集团(即公司及控股子公司/单位，下同)自主研发的化学药品。该药品拟用于在口服给药困难的情况下，以下疾病和症状的祛痰：肺结核、尘肺病、手术后。截至2025年1月，集团现阶段针对盐酸溴己新注射液的累计研发投入约为人民币164万元(未经审计)。根据IQVIACHPA最新数据，2023年，盐酸溴己新注射剂于中国境内(不包括港澳台地区)的销售额约为人民币15.89亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK0196","02196","BK1515","600196","BK0188","BK0012","BK0239","BK0060","BK0187","BK0175","BK0028","BK0096","BK1191","BK0183"],"gpt_icon":0},{"id":"2514788755","title":"復星醫藥(02196)：鹽酸替那帕諾片的上市許可申請獲國家藥監局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514788755","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514788755?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 18:14","pubTimestamp":1740564847,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，公司控股子公司上海复星医药产业发展有限公司(简称“复星医药产业”)获许可产品盐酸替那帕诺片(中国内地 商品名：万缇乐® )的上市许可申请于近日获国家药品监督管理局批准，本次获批适应症为用于控制对磷结合剂疗效不充分或不耐受的慢性肾脏病(CKD)成人透析患者的血清磷水平。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0096","BK0196","BK0028","600196","BK0175","BK0188","BK1515","BK0012","BK0187","BK0239","BK1191","BK1593","BK0060","02196"],"gpt_icon":0},{"id":"2514588749","title":"復星醫藥：公司對Gland Pharma未來的長期表現充滿信心，並將繼續推動其在全球市場的發展和增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2514588749","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514588749?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 18:09","pubTimestamp":1740564544,"startTime":"0","endTime":"0","summary":"有投资者向复星医药提问， 据印度媒体报道，复星医药准备出售印度公司glandpharma的所有股权，作价30亿美元，目前正与黑石集体洽谈，请问上述报道属实吗？谢谢！公司回答表示，投资者您好！Gland Pharma是公司全球化战略中的重要组成部分。截至目前，公司持有Gland Pharma 51.83%的股权。公司对Gland Pharma未来的长期表现充满信心，并将继续推动其在全球市场的发展和增长。感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226181519abddac96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226181519abddac96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1593","02196","BK1191","600196"],"gpt_icon":0},{"id":"2514874918","title":"復星醫藥：公司董事會已分別審議通過A股回購方案及H股回購方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2514874918","media":"互动易","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514874918?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 18:09","pubTimestamp":1740564542,"startTime":"0","endTime":"0","summary":"公司回答表示，投资者您好！公司始终将股东利益放在重要位置，高度重视市值管理工作。2025年1月22日，公司董事会已分别审议通过A股回购方案及H股回购方案，回购期间为自1月22日起6个月内，其中A股回购总金额不低于人民币3亿元且不超过人民币6亿元，H股回购股数不超过H股总数的5%。同时，公司将持续提升经营效率和盈利能力，不断提升对股东的回报。感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226181520a254b3e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226181520a254b3e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1593","BK1515","600196","02196"],"gpt_icon":0},{"id":"2514388415","title":"全球首款磷吸收抑制劑萬緹樂在中國獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2514388415","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514388415?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 17:30","pubTimestamp":1740562211,"startTime":"0","endTime":"0","summary":"南方财经2月26日电，复星医药（股票代码：600196.SH；02196.HK）宣布，控股子公司上海复星医药产业发展有限公司（“复星医药产业”）获独家开发和商业化许可的全新机制降磷创新药盐酸替那帕诺片（中国境内商品名：万缇乐?）用于控制对磷结合剂疗效不充分或不耐受的慢性肾脏病（CKD）成人透析患者的血清磷水平的药品注册申请于近日获国家药品监督管理局（NMPA）批准上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502263330389851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1191","02196","BK1593"],"gpt_icon":0},{"id":"2514137881","title":"真實生物二戰港交所：僅一款藥物上市分手復星後銷量暴跌 在研管線青黃不接距上市遙遙無期","url":"https://stock-news.laohu8.com/highlight/detail?id=2514137881","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514137881?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 17:26","pubTimestamp":1740561960,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　近日，创新药企真实生物科技有限公司二次向港交所递交上市申请，中金公司担任其独家保荐人。　　截至目前，阿兹夫定仍然是真实生物目前唯一上市产品，其收入占比高达100%。招股书显示，真实生物与复星医药产业的合作始于2022年。　　种种隐忧之下，真实生物二次赴港IPO，本质上是为续命研发和填补亏损的无奈之举。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-02-26/doc-inemuzuz3585070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","02196","BK1593","BK1515"],"gpt_icon":0},{"id":"2514887496","title":"復星醫藥控股子公司鹽酸溴己新注射液獲受理 研發投入164萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514887496","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514887496?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 17:24","pubTimestamp":1740561887,"startTime":"0","endTime":"0","summary":"2月26日，复星医药发布公告，控股子公司重庆药友制药有限责任公司就盐酸溴己新注射液的药品注册申请于近日获国家药品监督管理局受理。截至2025年1月，公司针对盐酸溴己新注射液的累计研发投入约为164万元。根据IQVIACHPA的最新数据，2023年盐酸溴己新注射剂在中国境内的销售额约为15.89亿元。2024年前三季度，复星医药实现收入309.12亿元，归母净利润20.11亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226181024a254b254&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226181024a254b254&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","600196","BK1191","BK1593","02196"],"gpt_icon":0},{"id":"2514884668","title":"復星醫藥控股子公司複方匹可硫酸鈉顆粒獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2514884668","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514884668?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 17:19","pubTimestamp":1740561540,"startTime":"0","endTime":"0","summary":"2月26日，复星医药发布公告，控股子公司苏州二叶制药有限公司近日获得国家药品监督管理局批准，上市药品为复方匹可硫酸钠颗粒。药品的规格为每袋含匹可硫酸钠10mg、氧化镁3.5g和无水枸橼酸12g，注册分类为化学药品3类。2024年前三季度，复星医药实现收入309.12亿元，归母净利润20.11亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022617280298936138&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022617280298936138&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600196","BK1593","02196","BK1191","BK1515"],"gpt_icon":0},{"id":"2514883000","title":"復星醫藥控股子公司獲鹽酸替那帕諾片上市許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2514883000","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514883000?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 16:44","pubTimestamp":1740559447,"startTime":"0","endTime":"0","summary":"2月26日，复星医药（600196/02196）发布公告，控股子公司复星医药产业获得盐酸替那帕诺片的上市许可，该药品用于控制慢性肾脏病（CKD）成人透析患者的血清磷水平。该药品的上市许可申请已于近日获得国家药品监督管理局批准，适应症为对磷结合剂疗效不充分或不耐受的患者。截至2025年1月，集团针对该药品的累计研发投入约为1.8亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502263330330856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK1593","BK1515","02196"],"gpt_icon":0},{"id":"2514883180","title":"復星醫藥(600196.SH)：複方匹可硫酸鈉顆粒上市註冊申請獲批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514883180","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514883180?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 16:34","pubTimestamp":1740558851,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，公司控股子公司苏州二叶制药有限公司就复方匹可硫酸钠颗粒的上市注册申请于近日获国家药品监督管理局批准。该药品主要用于结肠镜检查、X射线检查前的肠道清洁准备，用于必要时在外科手术前清洁肠道。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0096","BK0188","BK1515","BK0196","BK0187","BK0012","BK0060","BK0183","BK0239","BK1191","600196","02196","BK0175","BK0028","BK1593"],"gpt_icon":0}],"pageSize":16,"totalPage":9,"pageCount":6,"totalSize":133}]}}